Table 2.

Frequency of genomic rearrangements within the three different MRD groups.

MRD value EOI/Genomic rearrangement	≥1 × 10−2	<1 × 10−2	<1 × 10−3
	(n = 68)	(n = 47)	(n = 49)a
No rearrangement	37	39	36
DUX4-IGH	6	3	1
CRLF2-IGH	6	–	–
EBF1-PDGFR-ß	5	–	–
EPOR-IGH	5	–	1b
PAR1-Del	4	3	3 (2c)
other	6	2	8
	31 (46%)	8 (17%)	13 (26%)

EOI end of induction treatment

^aThis group included seven selected relapse cases with weakly positive or negative MRD

^bPatient had a relapse and was initially grouped as MRD-EOI “positive, not quantifiable”, but new MRD marker would re-assign this patient to the second group

^cTwo out of the three cases were included because of a relapse and “positive, not quantifiable” MRD